Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 16 daratumumab 9 Bortezomib 9 Lenalidomide 6 pomalidomide 4 carfilzomib 4 isatuximab 3 trametinib 2 selinexor 2 dabrafenib 2 Thalidomide 2 Prednisone 2 Melphalan 2 ulixertinib 1 trastuzumab biosimilar HLX02 1 talquetamab 1 sapanisertib 1 relatlimab 1 pertuzumab 1 palbociclib 1 osimertinib 1 omipalisib 1 montelukast 1 melflufen 1 larotrectinib 1 ipatasertib 1 erdafitinib 1 defactinib 1 darlin protein, Dictyostelium 1 copanlisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Multiple Myeloma × melflufen × Clear all

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡